I-SPY 2: Addition of Pembrolizumab to Neoadjuvant Chemotherapy in HER2-Negative Early Breast Cancer
Breast Cancer: A Review of Key Clinical Studies
MONARCH 2: Phase III Study of Abemaciclib + Fulvestrant in HR+/HER2- Advanced Breast Cancer After Progression on Endocrine Therapy
LOTUS: Investigation of Ipatasertib, a Novel Akt Inhibitor, in Combination With Paclitaxel as Frontline Therapy for Metastatic TNBC
KEYNOTE-086 (Cohort A): Phase II Evaluation of Pembrolizumab Monotherapy in Heavily Pretreated Metastatic TNBC
Conference CoverageEducationClinicalThoughtDecision SupportCCO Live EventsSlidesets & Resources
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Clinical Care Options, LLC. All Rights Reserved.